Core Insights - The National Medical Products Administration (NMPA) in China has approved Sanofi's two medicines for rare hematologic diseases: Qfitlia for hemophilia and Cablivi for acquired thrombotic thrombocytopenic purpura [1][2] - These approvals mark Sanofi's fourth and fifth in China this year, expanding its rare hematology portfolio [2][5] Group 1: Qfitlia - Qfitlia is indicated for routine prophylaxis to prevent or reduce bleeding episodes in pediatric patients aged 12 and older, and adults with severe hemophilia A [2][3] - The approval is based on ATLAS phase 3 studies showing significant bleed protection, with a 71% reduction in annualized bleeding rates (ABR) for patients without inhibitors and a 73% reduction for patients with inhibitors [3][7] - Nearly half of the patients in the open-label extension study experienced one or fewer bleeds, with 94% achieving target AT levels with minimal dose adjustments [7] Group 2: Cablivi - Cablivi is the first Nanobody targeted therapy for treating acquired thrombotic thrombocytopenic purpura in adults and adolescents aged 12 or older [4][5] - It targets von Willebrand factor (vWF) to inhibit the interaction between vWF and platelets, helping to prevent organ damage during the disease [5] - Approximately 2,700 patients are diagnosed with this condition annually in China [4]